Oral self-assembly nanoemulsion drives in vivo hepatic stellate cell-targeting drug delivery in liver fibrosis.

Xinjing Shen^1,2,3, Jie Deng^2,3, Aijiao Jiang^2,3, Qianqi Cai^2,3, Deyong Tian^2,3, Linlin Zhao^2,3, Jing Ye^2,3, Lie Zhang^1,4, Yucheng Xiang^2,3, Quan Zhang^1,2,3,5,6

¹Department of Neurosurgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.

²Key Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu, China.

³Institute of Materia Medica, Chengdu Medical College, Chengdu, China.

⁴School of Clinical Medicine, Chengdu Medical College, Chengdu, China.

⁵Development and Regeneration Key Laboratory of Sichuan Province, School of Basic Medical Sciences, Chengdu Medical College, Chengdu, China.

⁶Chengdu Nature's Grace Biological Technology Co., Ltd., Chengdu, China.

PubMed PMC DOI PDF

Abstract

Hepatic fibrosis is a chronic liver disease that requires long-term treatment and is characterized by the excessive accumulation of extracellular matrix (ECM), which is produced primarily by activated hepatic stellate cells (aHSCs). Oral medication represents a non-invasive and crucial strategy for prolonged therapy. However, achieving targeted drug delivery to aHSCs through oral administration re…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.